Effects of clazosentan, cilostazol, and statins on aneurysmal subarachnoid hemorrhage : A protocol for systematic review and meta-analysis
BACKGROUND: Aneurysmal subarachnoid hemorrhage (aSAH) is a disease caused by the infiltration of blood into the subarachnoid space due to the rupture of an intracranial aneurysm. It is a serious cerebrovascular disease, with a mortality rate of about 40% worldwide, which seriously threatens human life and health. Many drugs are used to treat aSAH and its complications, and some have been tested in systematic reviews and have shown good effects. But which drug has the best effect remains unclear. This network meta-analysis (NMA) aims to assess the effectiveness and feasibility of clazosentan, cilostazol, and statins in patients with aSAH.
METHODS: We will search for EMBASE.com, PubMed, the Cochrane Library, and Web of Science from inception to December 2019. Randomized controlled trials (RCTs) reporting efficacy and safety of clazosentan, cilostazol, and statins compared with the control, or compared with each other for the treatment of aSAH will be included. Two independent reviewers will assess the risk of bias of the included RCTs with the Cochrane "Risk of bias" tool. The pairwise meta-analysis will be performed with the random-effects model. The NMA will be performed in a Bayesian hierarchical framework using Markov Chain Monte Carlo method in WinBUGS 1.4.3. Egger test and funnel plot will be used to assess the publication bias. We will evaluate the quality of evidence for each outcome according to the GRADE approach.
RESULTS: The results of this NMA will be submitted to a peer-reviewed journal for publication.
CONCLUSION: This study will summarize up-to-date evidence to compare the efficacy and safety of clazosentan, cilostazol, and statins on aSAH.PROSPERO registration number: CRD42019147523.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
---|---|
Enthalten in: |
Medicine - 99(2020), 17 vom: 01. Apr., Seite e19902 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
He, Junfang [VerfasserIn] |
---|
Links: |
---|
Themen: |
3DRR0X4728 |
---|
Anmerkungen: |
Date Completed 11.05.2020 Date Revised 15.01.2021 published: Print Citation Status MEDLINE |
---|
doi: |
10.1097/MD.0000000000019902 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM309168155 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM309168155 | ||
003 | DE-627 | ||
005 | 20231225133321.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/MD.0000000000019902 |2 doi | |
028 | 5 | 2 | |a pubmed24n1030.xml |
035 | |a (DE-627)NLM309168155 | ||
035 | |a (NLM)32332668 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a He, Junfang |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effects of clazosentan, cilostazol, and statins on aneurysmal subarachnoid hemorrhage |b A protocol for systematic review and meta-analysis |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.05.2020 | ||
500 | |a Date Revised 15.01.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: Aneurysmal subarachnoid hemorrhage (aSAH) is a disease caused by the infiltration of blood into the subarachnoid space due to the rupture of an intracranial aneurysm. It is a serious cerebrovascular disease, with a mortality rate of about 40% worldwide, which seriously threatens human life and health. Many drugs are used to treat aSAH and its complications, and some have been tested in systematic reviews and have shown good effects. But which drug has the best effect remains unclear. This network meta-analysis (NMA) aims to assess the effectiveness and feasibility of clazosentan, cilostazol, and statins in patients with aSAH | ||
520 | |a METHODS: We will search for EMBASE.com, PubMed, the Cochrane Library, and Web of Science from inception to December 2019. Randomized controlled trials (RCTs) reporting efficacy and safety of clazosentan, cilostazol, and statins compared with the control, or compared with each other for the treatment of aSAH will be included. Two independent reviewers will assess the risk of bias of the included RCTs with the Cochrane "Risk of bias" tool. The pairwise meta-analysis will be performed with the random-effects model. The NMA will be performed in a Bayesian hierarchical framework using Markov Chain Monte Carlo method in WinBUGS 1.4.3. Egger test and funnel plot will be used to assess the publication bias. We will evaluate the quality of evidence for each outcome according to the GRADE approach | ||
520 | |a RESULTS: The results of this NMA will be submitted to a peer-reviewed journal for publication | ||
520 | |a CONCLUSION: This study will summarize up-to-date evidence to compare the efficacy and safety of clazosentan, cilostazol, and statins on aSAH.PROSPERO registration number: CRD42019147523 | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Dioxanes |2 NLM | |
650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
650 | 7 | |a Pyridines |2 NLM | |
650 | 7 | |a Pyrimidines |2 NLM | |
650 | 7 | |a Sulfonamides |2 NLM | |
650 | 7 | |a Tetrazoles |2 NLM | |
650 | 7 | |a clazosentan |2 NLM | |
650 | 7 | |a 3DRR0X4728 |2 NLM | |
650 | 7 | |a Cilostazol |2 NLM | |
650 | 7 | |a N7Z035406B |2 NLM | |
700 | 1 | |a Zhang, Li |e verfasserin |4 aut | |
700 | 1 | |a Yu, Yao |e verfasserin |4 aut | |
700 | 1 | |a Luo, Xinyue |e verfasserin |4 aut | |
700 | 1 | |a Wei, Min |e verfasserin |4 aut | |
700 | 1 | |a Chen, Gen |e verfasserin |4 aut | |
700 | 1 | |a Shen, Yanfei |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Medicine |d 1945 |g 99(2020), 17 vom: 01. Apr., Seite e19902 |w (DE-627)NLM000020737 |x 1536-5964 |7 nnns |
773 | 1 | 8 | |g volume:99 |g year:2020 |g number:17 |g day:01 |g month:04 |g pages:e19902 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/MD.0000000000019902 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 99 |j 2020 |e 17 |b 01 |c 04 |h e19902 |